spiriTED — TOUR006 in Thyroid Eye Disease

A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Study of TOUR006 in Thyroid Eye Disease (spiriTED) ClinicalTrials.gov ID: NCT06088979 Sponsor: Tourmaline Bio, Inc. Role: Sub-Investigator – Maja Kostic, MD, MMSc, PhD PI: Sara Wester, MD Phase 2b trial assessing efficacy and safety of TOUR006 (20 mg and 50 mg) versus placebo, administered subcutaneously every 8 weeks, in adults with moderate-to-severe thyroid eye disease.